The real-life effect of catechol-O-methyltransferase inhibition on non-motor symptoms in levodopa-treated Parkinson's disease: opicapone versus entacapone.

"Declarations Conflict of interestVL has received travel grants and honoraria for speaker-related activity from Bial, outside the submitted work. DvW has received travel grants and speaker fees from Bial, outside the submitted work. AR has received salary support from National institute of Health Research (NIHR) Clinical Research Network (CRN) South London, Guy's Hospital, Great Maze Pond, London SE1 9RT, UK; International Parkinson and Movement Disorder Society (MDS) 555 East Wells Street, Suite 1100, Milwaukee, WI 53202-3823 USA, outside the submitted work. KRC reports advisory board for AbbVie, UCB, GKC, Bial, Cynapsus, Novartis, Lobsor, Stada, Medtronic, Zambon, Profile, Sunovion, Roche, Theravance, Scion, Britannia; honoraria for lectures from AbbVie, Britannia, UCB, Mundipharma, Zambon, Novartis, Boeringer Ingelheim; grants (Investigator Initiated) from Britania Pharmaceuticals, AbbVie, UCB, GKC, Bial; academic grants from EU, IMI EU, Horizon 2020, Parkinson’s UK, NIHR, PDNMG, EU (Horizon 2020), Kirby Laing Foundation, NPF, MRC, Wellcome Trust, outside the submitted work. Conflict of interest VL has received travel grants and honoraria for speaker-related activity from Bial, outside the submitted work. DvW has received travel grants and speaker fees from Bial, outside the submitted work. AR has received salary support from National institute of Health Research (NIHR) Clinical Research Network (CRN) South London, Guy's Hospital, Great Maze Pond, London SE1 9RT, UK; International Parkinson and Movement Disorder Society (MDS) 555 East Wells Street, Suite 1100, Milwaukee, WI 53202-3823 USA, outside the submitted work. KRC reports advisory board for AbbVie, UCB, GKC, Bial, Cynapsus, Novartis, Lobsor, Stada, Medtronic, Zambon, Profile, Sunovion, Roche, Theravance, Scion, Britannia; honoraria for lectures from AbbVie, Britannia, UCB, Mundipharma, Zambon, Novartis, Boeringer Ingelheim; grants (Investigator Initiated) from Britania Pharmaceuticals, AbbVie, UCB, GKC, Bial; academic grants from EU, IMI EU, Horizon 2020, Parkinson’s UK, NIHR, PDNMG, EU (Horizon 2020), Kirby Laing Foundation, NPF, MRC, Wellcome Trust, outside the submitted work."

"The views expressed are those of the authors and not necessarily those of the NHS, NIHR or Department of Health. The authors acknowledge the support of the International Parkinson and Movement Disorder Society Non-Motor Parkinson’s disease Study Group, the NIHR London South Clinical Research Network, the NIHR Biomedical Research Centre, and the clinical research team at the Parkinson’s Foundation centre of excellence at King’s College Hospital and King’s College London. This article represents independent collaborative research part funded by the NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London."